About Kisspeptin
Kisspeptin is a neuropeptide encoded by the KISS1 gene and the master regulator of GnRH release. Research covers reproductive function, hypogonadism, and emotional brain processing.
Sexual Health
Kisspeptin
Reproductive Hormone Peptide
A neuropeptide studied for reproductive function and HPG axis regulation.
Phase IIResearch use only
Where to buy
Vendor offerings
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Best $/mg
Evidence level
Phase 2 trials
A neuropeptide encoded by the KISS1 gene that is the master upstream regulator of GnRH release and the HPG axis. Has reached phase II human trials for hypogonadism and IVF; also studied for sexual/emotional brain circuits.
Mechanism
Activates the KISS1R/GPR54 receptor to stimulate GnRH release.
Researched benefits
Restores HPG axis function
Stimulates GnRH neurons in the hypothalamus, which in turn drives LH and FSH release. Multiple human trials show robust LH pulses in both men and women, including patients with hypothalamic amenorrhea or congenital hypogonadism.
Trigger for ovulation induction in IVF
A kisspeptin bolus has been used as an alternative ovulation trigger to hCG in IVF cycles, with reduced ovarian hyperstimulation syndrome (OHSS) rates in some studies (Imperial College London group, multiple trials).
Sexual brain processing
Functional MRI studies in healthy men show that kisspeptin administration enhances limbic and paralimbic responses to sexual and bonding stimuli, suggesting a role beyond gonadotropin release.
Potential mood / anxiety modulation
Early human work and rodent data implicate kisspeptin in fear and anxiety circuits, though clinical relevance is unestablished.
Risks & cautions
- high
Hormone-sensitive conditions
Raises endogenous testosterone and estradiol via LH/FSH stimulation. Contraindicated in hormone-sensitive cancers (prostate, breast) and conditions like endometriosis.
- moderate
Theoretical effect on fertility timing
Inappropriate use during conception attempts could disrupt ovulatory timing. Pregnancy use is contraindicated outside controlled IVF protocols.
- moderate
Unknown long-term effects
Most human studies are single-dose or short-term. Chronic exogenous kisspeptin pharmacology in healthy adults is not characterized.
- low
Injection-site reactions
Subcutaneous and IV protocols are generally well tolerated in trial populations.
Dosing
0.1–1 mcg/kg subcutaneously or by IV bolus; trial protocols vary substantially by indication.
- Conservative
- 0.1 mcg/kg SC, single dose
- Standard
- 0.3 mcg/kg SC
- Aggressive
- 1 mcg/kg SC (research / IVF protocols)
Vial sizes
1mg / 5mg
Half-life
Very short
Route
subcutaneous, intravenous
Half-life is very short (~30 minutes). Kisspeptin-10 is the most commonly used research fragment. Kisspeptin-54 has been used in IVF trials. Dosing in published trials is typically weight-adjusted and given under medical supervision.
Contraindications
- Hormone-sensitive malignancies (prostate, breast, ovarian)
- Active endometriosis
- Pregnancy outside controlled fertility protocols
- Untreated pituitary tumors
- Concurrent fertility medications without supervision
In depth
Background
Kisspeptin was first identified in 1996 as a metastasis-suppressor protein (hence the alternative name "metastin"). Its role in reproduction was discovered in 2003 when two independent groups showed that loss-of-function mutations in KISS1R (also called GPR54) cause hypogonadotropic hypogonadism in humans. This established kisspeptin as the upstream gatekeeper of puberty and adult reproductive function.
The KISS1 gene encodes a 145-amino-acid precursor that is processed into several active fragments, named by length: kisspeptin-54, -14, -13, and -10. All share the same C-terminal decapeptide, which is sufficient for receptor binding.
Mechanism in depth
Kisspeptin neurons in the hypothalamus (arcuate nucleus and AVPV) project to GnRH neurons and release kisspeptin onto the KISS1R receptor on those neurons. Receptor activation:
- Depolarizes GnRH neurons via Gq-coupled signaling and inositol trisphosphate release
- Triggers pulsatile GnRH release into the hypophyseal portal system
- GnRH then drives anterior pituitary LH and FSH release
- LH/FSH stimulate gonadal sex steroid synthesis and gametogenesis
Kisspeptin neurons themselves are sensitive to sex steroid feedback (positive feedback for the LH surge in females, negative feedback otherwise), nutritional status (leptin), and stress.
Human evidence
Substantial for a research peptide:
- Hypogonadism: Kisspeptin administration restores LH pulsatility in patients with hypothalamic amenorrhea, hypogonadotropic hypogonadism, and constitutional pubertal delay.
- IVF: The Imperial College London group ran multiple trials using kisspeptin-54 as an ovulation trigger; phase II data showed reduced OHSS rates compared to hCG, with comparable oocyte maturation rates.
- Brain imaging: Comninos 2017 showed enhanced limbic/paralimbic activation to sexual and bonding stimuli in healthy men under kisspeptin.
- Mood: Small studies suggest acute anxiolytic effects but data is preliminary.
These trials are typically single-dose or short-course (days to weeks). Long-term exogenous administration in healthy adults has not been studied.
Animal evidence
Extensive. KISS1R knockout mice fail to enter puberty. Pharmacologic kisspeptin restores fertility in multiple rodent and primate models of hypogonadism. Animal work also implicates kisspeptin in seasonal reproduction, lactation suppression, and stress-mediated reproductive shutdown.
Stack synergy
- GnRH analogs (leuprolide, etc.) — pharmacologically redundant and potentially conflicting; do not combine.
- HCG / LH analogs — bypass kisspeptin's mechanism; combining is rarely productive for the same goal.
- Testosterone replacement — exogenous testosterone suppresses kisspeptin/GnRH/LH. Stacking defeats the purpose of using kisspeptin to drive endogenous gonadal output.
- PT-141 (bremelanotide) — different sexual-function pathway (melanocortin); theoretically complementary for libido endpoints, but no combined-use data exists.
Open questions
- Does chronic kisspeptin administration desensitize the KISS1R-GnRH axis (a known issue with sustained GnRH agonism)?
- What is the safe dosing window for non-clinical use, given the lack of long-term safety data?
- Can kisspeptin reliably restore HPG function in older men with age-related testosterone decline, or is the deficit downstream of kisspeptin signaling?
- Are the central (mood, libido) effects clinically meaningful at peripherally administered doses?
References
- 1.Jayasena C.N. et al. — A single injection of kisspeptin-54 temporarily increases LH pulsatility in healthy women (Clin Endocrinol, 2013)
- 2.Abbara A. et al. — Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy (J Clin Endocrinol Metab, 2015)
- 3.Comninos A.N. et al. — Kisspeptin modulates sexual and emotional brain processing in humans (J Clin Invest, 2017)
- 4.de Roux N. et al. — Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54 (PNAS, 2003)